{"filing":{"accession_number":"0001493152-26-042592","cik":"0000946644","ticker":"AIM","company_name":"AIM ImmunoTech Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-08","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226042592/form8-k.htm"},"events":[{"id":33332,"run_id":30644,"accession_number":"0001493152-26-042592","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"AIM ImmunoTech converted approximately $400,000 of debt into 1,749,434 shares of common stock at an average price of $0.228 per share. Item 3.02 explicitly discloses this as an unregistered sale of equity securities under Section 3(a)(9) of the Securities Act. This debt-to-equity conversion is a dilutive issuance that materially increases share count and would affect a reasonable investor's assessment of ownership dilution and capital structure.","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":36753,"accession_number":"0001493152-26-042592","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"AIM ImmunoTech converted approximately $400,000 of debt into 1,749,434 shares of common stock at an average price of $0.228 per share. Item 3.02 explicitly discloses this as an unregistered sale of equity securities under Section 3(a)(9) of the Securities Act. This debt-to-equity conversion is a dilutive issuance that materially increases share count and would affect a reasonable investor's assessment of ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:41:02.707423+00:00","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-09-14"}]}